Information Provided By: 
Fly News Breaks for December 16, 2015
ZTS
Dec 16, 2015 | 07:00 EDT
Piper Jaffray analyst Kevin Ellich calls Zoetis his favorite idea in 2016. Animal health industry dynamics remain favorable and the company's oral flea and tick medication, Simparica, should receive U.S. approval in the first half of 2016, Ellich tells investors in a research note. A "number of catalysts" could drive upside to Street estimates next year, the analyst contends. He reiterates an Overweight rating on Zoetis with a $58 price target.
News For ZTS From the Last 2 Days
There are no results for your query ZTS
